...

首页> 外文期刊>Journal of the American College of Surgeons >Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative) Discussion

【24h】

Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative) Discussion

机译：Neoadjuvant全身治疗患者阶段II / III乳腺癌腋生管理：CALGB 40601（HER2阳性）和CALGB 40603（三负）讨论结果

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of the American College of Surgeons》 |2017年第4期|共4页
作者
Henry-Tillman Ronda; Grobmyer Stephen; Wood William; Ollila David;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类外科学;
关键词

相似文献

外文文献
中文文献
专利

1. Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative) Discussion [J] . Henry-Tillman Ronda, Grobmyer Stephen, Wood William, Journal of the American College of Surgeons . 2017,第4期

机译：Neoadjuvant全身治疗患者阶段II / III乳腺癌腋生管理：CALGB 40601（HER2阳性）和CALGB 40603（三负）讨论结果
2. Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance) [J] . Golshan Mehra, Cirrincione Constance T., Sikov William M., Breast cancer research and treatment. . 2016,第2期

机译：新辅助疗法对II-III期HER2阳性乳腺癌患者的保乳资格和发生频率的影响：CALGB 40601（联盟）的手术结果
3. Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance) [J] . Sikov William M., Berry Donald A., Perou Charles M., Journal of Clinical Oncology . 2015,第1期

机译：在每周一次的紫杉醇新辅助治疗中加用卡铂和/或贝伐单抗后加剂量密集的阿霉素和环磷酰胺对II至III期三阴性乳腺癌病理完全缓解率的影响：CALGB 40603（联盟）
4. Results of treatment in patients with IIa - IIIast. breast cancer treated by combination of low-level laser therapy (LLLT) and surgery (5-year experience) [C] . V.A. Mikhailov, Ctr. of Laser Medicine, Moscow, CIS Selected Papers: Laser Use in Oncology . 1996

机译：IIa-IIIast患者的治疗结果。低水平激光疗法（LLLT）和手术相结合治疗乳腺癌（5年经验）
5. Coregistration of serial breast MR studies for augmenting neoadjuvant chemotherapy response evaluation in breast cancer patients. [D] . Chittineni, Ruparani. 2008

机译：增强乳腺癌患者新系列辅助化疗反应评估的系列乳房MR研究的核心。
6. Axillary Management of Stage II/III Breast Cancer Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-positive) and CALGB 40603 (Triple-negative) [O] . David W Ollila, Constance T Cirrincione, Donald A Berry, -1

机译：新辅助系统疗法治疗的II / III期乳腺癌患者的腋窝管理：CALGB 40601（HER2阳性）和CALGB 40603（三阴性）的结果
7. Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative) [O] . David W. Ollila, Constance T. Cirrincione, Donald A. Berry, 2017

机译：Neoadjuvant全身治疗患者患者Ⅱ期/ III乳腺癌腋生管理：CALGB 40601（HER2阳性）和CALGB 40603的结果（三负）

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号